Forget Ozempic: This Obesity-Drug Giant Grabs GLP-1 Gold
As GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
A recession-friendly withdrawal plan prioritizes sustainability. Find rules and examples to keep your withdrawals aligned with market conditions.
21,577 articlesAs GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
Meta Platforms signs a multiyear pact with AMD for up to 6 GW of customized GPUs, bolstering a multi-vendor AI chip s...
Two decades after a flopped acting debut, David Ellison’s Skydance is moving from indie financier to potential indust...
This deep dive breaks down alto 2025 earnings, focusing on Q4 results, revenue growth, and what management signals fo...
Markets pivot as reports say iran’s supreme leader injured; investors reassess oil supply risk, sanctions, and possib...
A prominent investor dumped a multi‑million stake in a biotech stock that’s up double digits. This article explains w...
Evernorth has filed Form S-4 as it advances a merger with Armada Acquisition Corp. II to take a Nasdaq-listed XRP tre...
Microsoft shares fell Tuesday as investors reassessed the cost of OpenAI bets and growing capital needs, even after a...
A closer look at how Lawrence Calcano built iCapital into a leading wealth-tech platform for alternatives. Learn the ...
Ferrari delivered a quarter that topped estimates, yet the stock moved lower. This piece deciphers what drove the bea...
May presents a rare chance to own a glorious growth stock hand with enduring momentum. This guide breaks down why one...
The VanEck BDC Income ETF offers a high 13% quarterly yield by investing in business development companies. Yet the f...